Navigation Links
Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
Date:12/9/2008

itional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release

and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharm.com.


    [ALXN-G]

Safe Harbor Statement

This news release contains forward-looking statements, including statements related to potential health and medical benefits from Soliris. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that pending litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2008 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of thes
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
2. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
3. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
6. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
9. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
10. NIST studies how new helium ion microscope measures up
11. SpectraCell Laboratories Now Measures Vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... is scheduled to speak at the Jefferies 2015 Global ... the company,s President and CEO, will discuss the company,s ... scheduled for Tuesday, June 2, 2015 at 8:00 a.m. ... live during the conference and will be available to ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 BioNorth ... serving and representing the life sciences industry in ... of Directors meeting at The Foundry in Dallas ... the organization brought together a broad spectrum of ... underscored the organization's early successes in partnering with ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Foundation announced an agreement to underwrite a joint effort ... to search for personalized cancer therapies through biomarker research. ... will provide 2.5 million euros over the next five ... VHIO.  MGH has also committed to match up to ...
... Nov. 16, 2011 Fate ... Patent and Trademark Office has granted a patent covering ...  U.S. Patent No. 8,044,201 entitled "Stem Cell Cultures" claims ... well as compositions and cell culture media comprising Thiazovivin. ...
... scientists have developed a method for stacking synthetic DNA ... that may lead to more accurate measurements for research ... employ metal electrodes coated with enzymes that react with ... measured. But the inefficiency of those sensors leads to ...
Cached Biology Technology:BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital in Biomarker Research for Personalized Cancer Therapies 2Fate Therapeutics Strengthens Its iPSC Platform 2Fate Therapeutics Strengthens Its iPSC Platform 3New biosensor benefits from melding of carbon nanotubes, DNA 2
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... 20 May 2012. The Stem Cells and Cancer Research ... Vall d,Hebrn Institute of Oncology (VHIO) has identified the ... used in clinical trials for colon cancer treatment. The ... with Professor Alberto Muozs laboratory at the Instituto de ...
... PHOENIX, May 18, 2012 /PRNewswire-iReach/ -- With ... out of sight, and research to find "cures" continuing ... remain "a few years away," a small but growing ... human consciousness. A number of healing practices that rely ...
... did not set out to discover one of the longest ... and a team of researchers all current or former ... published in Scientific Reports . Their findings shed ... lead to widespread, yet largely invisible, disruptions of ecological interaction ...
Cached Biology News:Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Stanford scientists document fragile land-sea ecological chain 2
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
...
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
Biology Products: